Bullous Keratopathy Market

Explore FMI’s in-depth Coverage on the Bullous Keratopathy Market, offering Key Insights across Major Regions and Segments

Bullous Keratopathy Market by Therapies, Treatment, & Region | Forecast 2023 to 2033

Bullous Keratopathy Market Snapshot (2023 to 2033)

The global bullous keratopathy market was valued at US$ 410 Million in 2022. By 2023, the market is forecast to reach a valuation of US$ 427.54 Million. During the 2023 to 2033 assessment period, a CAGR of 4.3% is anticipated, with an anticipated closing value of US$ 650 Million.

Bullous keratopathies are much less common than they used to be as surgery techniques and implants have enhanced. Complications from cataract surgery used to be the most common cause of bullous keratopathy. Currently, the most common cause of bullous keratopathy is complications due to glaucoma surgery.

Occasionally, bullous keratopathy may be caused by corneal dystrophy. Corneal dystrophies are a group of genetic conditions that result in abnormal material accumulating within the cornea. Rarely, a few other eye conditions or blunt-force trauma to the eye can result in bullous keratopathy.

The ultimate method of curing bullous keratopathy is a corneal transplant. A corneal transplant replaces the affected cornea with a donor. This may include transplant techniques such as a penetrating keratoplasty to replace the entire cornea, a Descemet Stripping Endothelial Keratoplasty (DSEK), Descemet Stripping Automated Endothelial Keratoplasty (DSAEK), or Descemet Membrane Endothelial Keratoplasty (DMEK) to replace the just the Descemet membrane.

Bullous keratopathy has many treatment options including both medicinal and surgical. Medical management options for bullous keratopathy include lubricants, steroids, hyperosmotic agents in the form of sodium chloride drops and ointment, anti-glaucoma drugs, and antibiotics. Other surgical management options for bullous keratopathy include Amniotic membrane grafting (AMG), annular keratotomy, anterior stromal puncture, and basement membrane polishing, among others.

EO2002, a first-in-class, non-surgical, magnetic cell-based therapy with the ability to modify disease, was developed by Emmecell through its exclusive Magnetic Cell Delivery (MCD) nanoparticle platform. It provides easier access to treatment before the disease becomes disabling and painful, and has the potential to prevent or delay the onset of more serious and invasive surgical procedures, including corneal transplantation. EO2002 is being evaluated in Phase I, a prospective, multicenter, open-label, dose-escalation study (EMME-01″) designed to assess the safety and tolerability of EO2002 with and without endothelial brushing (EB) or Descemet stripping (DS) in eyes with corneal edema secondary to corneal endothelial dysfunction that qualifies for surgery involving full-thickness corneal transplantation or endothelial keratoplasty.

Report Attribute	Details
Market Value in 2022	US$ 410 Million
Expected Market Value (2023)	US$ 427.54 Million
Anticipated Forecast Value (2033)	US$ 650 Million
Projected Growth Rate (2023 to 2033)	CAGR 4.3%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2017 to 2022 Bullous Keratopathy Demand Analysis vs. Forecast 2023 to 2033

The bullous keratopathy market was valued at US$ 410 Million in 2022 and expanded with a CAGR of 4.2% between 2018 and 2022. Rising cases of cataract surgeries and the advent of advanced technologies in corneal transplant and implant surgeries are proving to be game changers in market expansion. Considering these factors, the bullous Keratopathy market is expected to possess a valuation of US$ 650 Million, growing with a CAGR of 4.3%.

Which are Some Prominent Drivers of the Bullous Keratopathy market?

Complications from Cataract Surgeries augmenting Market Growth

Rising complications from cataract surgeries and glaucoma surgeries and the growing prevalence of eye disorders are driving the market of bullous keratopathy. Furthermore, the adoption of surgical management options for bullous keratopathy including Amniotic membrane grafting (AMG), annular keratotomy, anterior stromal puncture, basement membrane polishing, etc. is boosting the growth of this market. Cataract surgery remained the leading cause of endothelial dysfunction/bullous keratopathy (39.9%), followed by combined surgery (23.0%) and FED (11.1%). FED, Fuchs’ endothelial dystrophy.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are the Challenges Projected to be Faced by the Market?

Increased risk factors of the surgery

Most people do well with bullous Keratopathy surgery. But complications can happen. Possible complications are Keratitis, perforation of the eye, extrusion of your ring, eye swelling, movement of your ring, night halos or glare, chronic eye pain, infections, etc. are expected to hamper the growth of the market during the forecast period. Furthermore, the high cost of ophthalmology devices and surgical procedures is anticipated to restrain the growth of this market during the forecast period.

Increase in risk of surgery failure

There is a risk that surgery might not correct the vision as much as expected. It might cause another vision problem like Astigmatism, where the curvature of the cornea becomes irregular. Some people who have corneal ring implantation may need an adjustment surgery to get a better outcome which will restrict the market growth.

Region-Wise Insights

What are the growth avenues for Bullous Keratopathy in North America?

Favorable Reimbursement policies driving the market

North America dominated the industry in 2021 and accounted for the largest share of around 59% of the overall revenue. Domicile of major market players, efficient reimbursement policies, and increasing Research and Development activities related to bullous Keratopathy are the factors expected to drive the region’s growth further.

North America's bullous keratopathy market was worth over US$ 190 Million in 2021. This is credited to the rising geriatric population base and the greater susceptibility of aging people to several chronic ailments, such as diabetes. Diabetic people are more prone to develop eye diseases that lead to vision loss. National Eye Institute estimates suggest that over 30,000 Americans undergo corneal transplants to replace injured and diseased corneas, creating numerous growth opportunities for the bullous Keratopathy market.

Surgical Incidences of Eye diseases to spur bullous keratopathy demand in Europe

Europe's bullous keratopathy market held over 19.1% business share in 2022 and is slated to record an appreciable target valuation by 2033. The regional industry is fuelled by the growing number of eye surgeries led by the prevalence of several eye disorders in Europe.

The increasing Research and Development investments and practices focused on developing advanced corneal implants will create favorable regional market statistics for the expansion of the bullous keratopathy market.

Category-Wise Insights

The hospital segment dominates the market with a revenue share of 58%

The hospital segment dominated the industry in 2021. The segment accounted for the largest revenue share of more than 58% with a revenue generation of US$ 150 Million in 2022 and is expected to register a lucrative CAGR over the forecast period.

The presence of highly skilled surgeons, the rising number of patients, and access to transnational eye banks are the factors anticipated to drive the segment growth.

Amniotic Membrane Grafting dominating in terms of Surgical Procedures

Amniotic membrane grafting segment accounts for the highest revenue share in the market. In this technique, first, the loose epithelium is removed with the help of a sponge or a blade. This results in a large epithelial defect, usually sparing the limbus. A required amniotic membrane is cut and placed over the cornea with the stromal side towards the cornea, which is sticky compared to the basement membrane. The AMG is then attached to the cornea with the help of interrupted stay sutures. If needed, a BCL can also be placed. Amniotic membrane transplantation is a successful adjunctive method in achieving corneal epithelization which will propel the growth of this segment during the forecast period.

Anti-Glaucoma Drugs lead the market for the postoperative period

These drugs are the most prevalent in primary medical management procedures. The drugs commonly employed are beta-blockers and alpha agonists-these work by reducing intraocular pressure, which reduces corneal edema and thickness in the postoperative period. Miotics and prostaglandins are avoided because they usually aggravate inflammation. Carbonic anhydrase inhibitors are also avoided as they are epitheliotoxic.

Start-ups in Bullous Keratopathy Market

Founded in 2015, Cellusion is a Japan-based Developer of iPS cell-based regenerative technology for bullous keratopathy. The regenerative material is developed by using iPS cell-derived cell transplantation for corneal endothelium replacement. The iPS cells are injected into the cornea for treating bullous keratopathy. It received funding of USD 14.7 million from Toyo Seikan Kaisha, UTEC, and 5 more.
Founded in 2016, Allotex is a Zurich, Switzerland-based company that is developing therapeutic solutions for the treatment of presbyopia, hyperopia, myopia, and astigmatism. The therapy is based on tissue addition technology that utilizes precisely-shaped human corneal allografts to create contact lenses or lens inserts. The corneal allografts can be placed on top of or just under Bowman’s (no need to place them deep in the cornea). It can be made in any shape, diameter, and thickness.

Market Competition

Key players in the Bullous Keratopathy market are- Hoffmann-La Roche Ltd, Regeneron, Pharmaceuticals, Inc., Pfizer, Inc., Bayer AG, Cellusion, CRSTEurope, Barraquer Eye Hospital, Planchard Eye & Laser Center, and Medscape. Some recent developments in the bullous keratopathy market are:

In September 2022: Celregen and Cellusion Inc. signed an exclusive license agreement for corneal endothelial cell regenerative therapy in Greater China.
In July 2022: Carl Zeiss Meditec and Precise Bio announced a partnership in the development and commercialization of tissue-based implants for ophthalmology.

Report Scope

Report Attribute	Details
Market Value in 2023	US$ 427.54 Million
Market Value in 2033	US$ 650 Million
Growth Rate	CAGR of 4.3% from 2023 to 2033
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in US$ Million and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered	Therapies Treatment End Users Region
Regions Covered	North America Latin America Europe South Asia & Pacific East Asia Middle East & Africa
Key Countries Profiled	USA Canada Brazil Mexico Mexico Germany UK France Spain Italy India Malaysia Singapore Thailand China Japan South Korea Australia New Zealand GCC countries South Africa Israel
Key Companies Profiled	Hoffmann-La Roche Ltd Regeneron Pharmaceuticals Pfizer Inc. Bayer AG Cellusion CRSTEurope Barraquer Eye Hospital Planchard Eye & Laser Center Medscape
Customization	Available Upon Request

Key Segments Profiled in the Bullous Keratopathy Market Industry Survey

Bullous Keratopathy Market by Therapies:

Emmecell
- Drug Description
- Regulatory Milestones
- Safety and Efficiency
- Product Profile
Cellusion
- Drug Description
- Other Development Activities
- Clinical Development
- Safety and Efficiency
- Product Profile

Bullous Keratopathy Market by End User:

Hospitals
Surgical Centers

Bullous Keratopathy Market by Treatment:

Medical Management
- Lubricants
- Steroids
- Hyperosmotic agents
- Anti- Glaucoma drugs
- Antibiotics
- Amniotic Membrane Grafting (AMG)
- Annular Keratotomy
- Anterior Stromal Puncture

Bullous Keratopathy Market by Region:

North America
Latin America
Europe
South Asia & Pacific
East Asia
Middle East & Africa

Frequently Asked Questions

What is the anticipated growth of the Bullous Keratopathy market until 2033?

FMI projects the global Bullous Keratopathy market to expand at a 4.3% value CAGR by 2033.

What is the estimated market value of the Bullous Keratopathy market expected in 2022?

The global Bullous Keratopathy market is estimated at a market value of US$ 410 Million in 2022.

What is the estimated market value of the Bullous Keratopathy market expected in 2033?

The global Bullous Keratopathy market is expected to garner a market value of US$ 650 Million by 2033.

Which region is forecast to be the most lucrative for Bullous Keratopathy market growth?

FMI has projected North America to be one of the most profitable regions for the Bullous Keratopathy market.

Table of Content

1. Executive Summary | Bullous Keratopathy Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033

        5.3.1. Medical Management

            5.3.1.1. Lubricants

            5.3.1.2. Steroids

            5.3.1.3. Hyperosmotic Agents

            5.3.1.4. Anti-Glaucoma Drugs

            5.3.1.5. Antibiotics

        5.3.2. Surgical Management

            5.3.2.1. AMillioniotic Membrane Grafting (AMG)

            5.3.2.2. Annular Keratotomy

            5.3.2.3. Anterior Stromal Puncture

    5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapies

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Therapies, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapies, 2023 to 2033

        6.3.1. Emmecell

            6.3.1.1. Drug Description

            6.3.1.2. Regulatory Milestones

            6.3.1.3. Safety and Efficacy

            6.3.1.4. Product Profile

        6.3.2. Cellusion

            6.3.2.1. Drug Description

            6.3.2.2. Clinical Development

            6.3.2.3. Other Development Activities

            6.3.2.4. Safety and Efficacy

            6.3.2.5. Product Profile

    6.4. Y-o-Y Growth Trend Analysis By Therapies, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Therapies, 2023 to 2033

7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By End Users, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users, 2023 to 2033

        7.3.1. Hospitals

        7.3.2. Surgical Centers

    7.4. Y-o-Y Growth Trend Analysis By End Users, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By End Users, 2023 to 2033

8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. South Asia & Pacific

        8.3.5. East Asia

        8.3.6. Middle East and Africa (MEA)

    8.4. Market Attractiveness Analysis By Region

9. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. United States of America

            9.2.1.2. Canada

        9.2.2. By Treatment

        9.2.3. By Therapies

        9.2.4. By End Users

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Treatment

        9.3.3. By Therapies

        9.3.4. By End Users

    9.4. Key Takeaways

10. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Treatment

        10.2.3. By Therapies

        10.2.4. By End Users

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Treatment

        10.3.3. By Therapies

        10.3.4. By End Users

    10.4. Key Takeaways

11. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United Kingdom

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Treatment

        11.2.3. By Therapies

        11.2.4. By End Users

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Treatment

        11.3.3. By Therapies

        11.3.4. By End Users

    11.4. Key Takeaways

12. South Asia & Pacific Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Malaysia

            12.2.1.3. Singapore

            12.2.1.4. Thailand

            12.2.1.5. Australia

            12.2.1.6. New Zealand

            12.2.1.7. Rest of South Asia & Pacific

        12.2.2. By Treatment

        12.2.3. By Therapies

        12.2.4. By End Users

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Treatment

        12.3.3. By Therapies

        12.3.4. By End Users

    12.4. Key Takeaways

13. East Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Treatment

        13.2.3. By Therapies

        13.2.4. By End Users

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Treatment

        13.3.3. By Therapies

        13.3.4. By End Users

    13.4. Key Takeaways

14. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Treatment

        14.2.3. By Therapies

        14.2.4. By End Users

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Treatment

        14.3.3. By Therapies

        14.3.4. By End Users

    14.4. Key Takeaways

15. Key Countries Analysis

    15.1. United States of America

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Treatment

            15.1.2.2. By Therapies

            15.1.2.3. By End Users

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Treatment

            15.2.2.2. By Therapies

            15.2.2.3. By End Users

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Treatment

            15.3.2.2. By Therapies

            15.3.2.3. By End Users

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Treatment

            15.4.2.2. By Therapies

            15.4.2.3. By End Users

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Treatment

            15.5.2.2. By Therapies

            15.5.2.3. By End Users

    15.6. United Kingdom

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Treatment

            15.6.2.2. By Therapies

            15.6.2.3. By End Users

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Treatment

            15.7.2.2. By Therapies

            15.7.2.3. By End Users

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Treatment

            15.8.2.2. By Therapies

            15.8.2.3. By End Users

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Treatment

            15.9.2.2. By Therapies

            15.9.2.3. By End Users

    15.10. India

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Treatment

            15.10.2.2. By Therapies

            15.10.2.3. By End Users

    15.11. Malaysia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Treatment

            15.11.2.2. By Therapies

            15.11.2.3. By End Users

    15.12. Singapore

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Treatment

            15.12.2.2. By Therapies

            15.12.2.3. By End Users

    15.13. Thailand

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Treatment

            15.13.2.2. By Therapies

            15.13.2.3. By End Users

    15.14. Australia

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Treatment

            15.14.2.2. By Therapies

            15.14.2.3. By End Users

    15.15. New Zealand

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Treatment

            15.15.2.2. By Therapies

            15.15.2.3. By End Users

    15.16. China

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Treatment

            15.16.2.2. By Therapies

            15.16.2.3. By End Users

    15.17. Japan

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Treatment

            15.17.2.2. By Therapies

            15.17.2.3. By End Users

    15.18. South Korea

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Treatment

            15.18.2.2. By Therapies

            15.18.2.3. By End Users

    15.19. GCC Countries

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Treatment

            15.19.2.2. By Therapies

            15.19.2.3. By End Users

    15.20. South Africa

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Treatment

            15.20.2.2. By Therapies

            15.20.2.3. By End Users

    15.21. Israel

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2022

            15.21.2.1. By Treatment

            15.21.2.2. By Therapies

            15.21.2.3. By End Users

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Treatment

        16.3.3. By Therapies

        16.3.4. By End Users

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Hoffmann-La Roche Ltd.,

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. Regeneron

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. Pfizer, Inc.,

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. Bayer AG

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. Cellusion

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. CRSTEurope

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Barraquer Eye Hospital

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Planchard Eye & Laser Center

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. Medscape

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Eyewiki

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

List of Tables

Table 1: Global Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 3: Global Value (US$ Million) Forecast by Therapies, 2018 to 2033

Table 4: Global Value (US$ Million) Forecast by End Users, 2018 to 2033

Table 5: North America Value (US$ Million) Forecast by Country, 2018 to 2033

Table 6: North America Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 7: North America Value (US$ Million) Forecast by Therapies, 2018 to 2033

Table 8: North America Value (US$ Million) Forecast by End Users, 2018 to 2033

Table 9: Latin America Value (US$ Million) Forecast by Country, 2018 to 2033

Table 10: Latin America Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 11: Latin America Value (US$ Million) Forecast by Therapies, 2018 to 2033

Table 12: Latin America Value (US$ Million) Forecast by End Users, 2018 to 2033

Table 13: Europe Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Europe Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 15: Europe Value (US$ Million) Forecast by Therapies, 2018 to 2033

Table 16: Europe Value (US$ Million) Forecast by End Users, 2018 to 2033

Table 17: South Asia & Pacific Value (US$ Million) Forecast by Country, 2018 to 2033

Table 18: South Asia & Pacific Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 19: South Asia & Pacific Value (US$ Million) Forecast by Therapies, 2018 to 2033

Table 20: South Asia & Pacific Value (US$ Million) Forecast by End Users, 2018 to 2033

Table 21: East Asia Value (US$ Million) Forecast by Country, 2018 to 2033

Table 22: East Asia Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 23: East Asia Value (US$ Million) Forecast by Therapies, 2018 to 2033

Table 24: East Asia Value (US$ Million) Forecast by End Users, 2018 to 2033

Table 25: MEA Value (US$ Million) Forecast by Country, 2018 to 2033

Table 26: MEA Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 27: MEA Value (US$ Million) Forecast by Therapies, 2018 to 2033

Table 28: MEA Value (US$ Million) Forecast by End Users, 2018 to 2033

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Value (US$ Million) by Treatment, 2023 to 2033

Figure 2: Global Value (US$ Million) by Therapies, 2023 to 2033

Figure 3: Global Value (US$ Million) by End Users, 2023 to 2033

Figure 4: Global Value (US$ Million) by Region, 2023 to 2033

Figure 5: Global Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 6: Global Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 7: Global Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 8: Global Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 9: Global Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 10: Global Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 11: Global Value (US$ Million) Analysis by Therapies, 2018 to 2033

Figure 12: Global Value Share (%) and BPS Analysis by Therapies, 2023 to 2033

Figure 13: Global Y-o-Y Growth (%) Projections by Therapies, 2023 to 2033

Figure 14: Global Value (US$ Million) Analysis by End Users, 2018 to 2033

Figure 15: Global Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 16: Global Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 17: Global Attractiveness by Treatment, 2023 to 2033

Figure 18: Global Attractiveness by Therapies, 2023 to 2033

Figure 19: Global Attractiveness by End Users, 2023 to 2033

Figure 20: Global Attractiveness by Region, 2023 to 2033

Figure 21: North America Value (US$ Million) by Treatment, 2023 to 2033

Figure 22: North America Value (US$ Million) by Therapies, 2023 to 2033

Figure 23: North America Value (US$ Million) by End Users, 2023 to 2033

Figure 24: North America Value (US$ Million) by Country, 2023 to 2033

Figure 25: North America Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 26: North America Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 27: North America Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 28: North America Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 29: North America Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 30: North America Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 31: North America Value (US$ Million) Analysis by Therapies, 2018 to 2033

Figure 32: North America Value Share (%) and BPS Analysis by Therapies, 2023 to 2033

Figure 33: North America Y-o-Y Growth (%) Projections by Therapies, 2023 to 2033

Figure 34: North America Value (US$ Million) Analysis by End Users, 2018 to 2033

Figure 35: North America Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 36: North America Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 37: North America Attractiveness by Treatment, 2023 to 2033

Figure 38: North America Attractiveness by Therapies, 2023 to 2033

Figure 39: North America Attractiveness by End Users, 2023 to 2033

Figure 40: North America Attractiveness by Country, 2023 to 2033

Figure 41: Latin America Value (US$ Million) by Treatment, 2023 to 2033

Figure 42: Latin America Value (US$ Million) by Therapies, 2023 to 2033

Figure 43: Latin America Value (US$ Million) by End Users, 2023 to 2033

Figure 44: Latin America Value (US$ Million) by Country, 2023 to 2033

Figure 45: Latin America Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 46: Latin America Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 47: Latin America Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 48: Latin America Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 49: Latin America Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 50: Latin America Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 51: Latin America Value (US$ Million) Analysis by Therapies, 2018 to 2033

Figure 52: Latin America Value Share (%) and BPS Analysis by Therapies, 2023 to 2033

Figure 53: Latin America Y-o-Y Growth (%) Projections by Therapies, 2023 to 2033

Figure 54: Latin America Value (US$ Million) Analysis by End Users, 2018 to 2033

Figure 55: Latin America Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 56: Latin America Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 57: Latin America Attractiveness by Treatment, 2023 to 2033

Figure 58: Latin America Attractiveness by Therapies, 2023 to 2033

Figure 59: Latin America Attractiveness by End Users, 2023 to 2033

Figure 60: Latin America Attractiveness by Country, 2023 to 2033

Figure 61: Europe Value (US$ Million) by Treatment, 2023 to 2033

Figure 62: Europe Value (US$ Million) by Therapies, 2023 to 2033

Figure 63: Europe Value (US$ Million) by End Users, 2023 to 2033

Figure 64: Europe Value (US$ Million) by Country, 2023 to 2033

Figure 65: Europe Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 66: Europe Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 67: Europe Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 68: Europe Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 69: Europe Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 70: Europe Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 71: Europe Value (US$ Million) Analysis by Therapies, 2018 to 2033

Figure 72: Europe Value Share (%) and BPS Analysis by Therapies, 2023 to 2033

Figure 73: Europe Y-o-Y Growth (%) Projections by Therapies, 2023 to 2033

Figure 74: Europe Value (US$ Million) Analysis by End Users, 2018 to 2033

Figure 75: Europe Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 76: Europe Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 77: Europe Attractiveness by Treatment, 2023 to 2033

Figure 78: Europe Attractiveness by Therapies, 2023 to 2033

Figure 79: Europe Attractiveness by End Users, 2023 to 2033

Figure 80: Europe Attractiveness by Country, 2023 to 2033

Figure 81: South Asia & Pacific Value (US$ Million) by Treatment, 2023 to 2033

Figure 82: South Asia & Pacific Value (US$ Million) by Therapies, 2023 to 2033

Figure 83: South Asia & Pacific Value (US$ Million) by End Users, 2023 to 2033

Figure 84: South Asia & Pacific Value (US$ Million) by Country, 2023 to 2033

Figure 85: South Asia & Pacific Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 86: South Asia & Pacific Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 87: South Asia & Pacific Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 88: South Asia & Pacific Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 89: South Asia & Pacific Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 90: South Asia & Pacific Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 91: South Asia & Pacific Value (US$ Million) Analysis by Therapies, 2018 to 2033

Figure 92: South Asia & Pacific Value Share (%) and BPS Analysis by Therapies, 2023 to 2033

Figure 93: South Asia & Pacific Y-o-Y Growth (%) Projections by Therapies, 2023 to 2033

Figure 94: South Asia & Pacific Value (US$ Million) Analysis by End Users, 2018 to 2033

Figure 95: South Asia & Pacific Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 96: South Asia & Pacific Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 97: South Asia & Pacific Attractiveness by Treatment, 2023 to 2033

Figure 98: South Asia & Pacific Attractiveness by Therapies, 2023 to 2033

Figure 99: South Asia & Pacific Attractiveness by End Users, 2023 to 2033

Figure 100: South Asia & Pacific Attractiveness by Country, 2023 to 2033

Figure 101: East Asia Value (US$ Million) by Treatment, 2023 to 2033

Figure 102: East Asia Value (US$ Million) by Therapies, 2023 to 2033

Figure 103: East Asia Value (US$ Million) by End Users, 2023 to 2033

Figure 104: East Asia Value (US$ Million) by Country, 2023 to 2033

Figure 105: East Asia Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 106: East Asia Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 107: East Asia Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 108: East Asia Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 109: East Asia Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 110: East Asia Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 111: East Asia Value (US$ Million) Analysis by Therapies, 2018 to 2033

Figure 112: East Asia Value Share (%) and BPS Analysis by Therapies, 2023 to 2033

Figure 113: East Asia Y-o-Y Growth (%) Projections by Therapies, 2023 to 2033

Figure 114: East Asia Value (US$ Million) Analysis by End Users, 2018 to 2033

Figure 115: East Asia Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 116: East Asia Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 117: East Asia Attractiveness by Treatment, 2023 to 2033

Figure 118: East Asia Attractiveness by Therapies, 2023 to 2033

Figure 119: East Asia Attractiveness by End Users, 2023 to 2033

Figure 120: East Asia Attractiveness by Country, 2023 to 2033

Figure 121: MEA Value (US$ Million) by Treatment, 2023 to 2033

Figure 122: MEA Value (US$ Million) by Therapies, 2023 to 2033

Figure 123: MEA Value (US$ Million) by End Users, 2023 to 2033

Figure 124: MEA Value (US$ Million) by Country, 2023 to 2033

Figure 125: MEA Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 126: MEA Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 127: MEA Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 128: MEA Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 129: MEA Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 130: MEA Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 131: MEA Value (US$ Million) Analysis by Therapies, 2018 to 2033

Figure 132: MEA Value Share (%) and BPS Analysis by Therapies, 2023 to 2033

Figure 133: MEA Y-o-Y Growth (%) Projections by Therapies, 2023 to 2033

Figure 134: MEA Value (US$ Million) Analysis by End Users, 2018 to 2033

Figure 135: MEA Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 136: MEA Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 137: MEA Attractiveness by Treatment, 2023 to 2033

Figure 138: MEA Attractiveness by Therapies, 2023 to 2033

Figure 139: MEA Attractiveness by End Users, 2023 to 2033

Figure 140: MEA Attractiveness by Country, 2023 to 2033